Related references
Note: Only part of the references are listed.Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis
Robert J. Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Ali Manouchehrinia et al.
NEUROLOGY (2020)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Ludwig Kappos et al.
JAMA NEUROLOGY (2020)
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
Madeline Bross et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Serum neurofilament light as a biomarker in progressive multiple sclerosis
Raju Kapoor et al.
NEUROLOGY (2020)
Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Simon Thebault et al.
SCIENTIFIC REPORTS (2020)
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode
Tatiana Plavina et al.
JAMA NETWORK OPEN (2020)
Silent progression in disease activity-free relapsing multiple sclerosis
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2019)
Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
I Dekker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Claire Bridel et al.
JAMA NEUROLOGY (2019)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
Ester Canto et al.
JAMA NEUROLOGY (2019)
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Christian Barro et al.
BRAIN (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
R. J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis
Tanuja Chitnis et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Long-Term Evolution of Multiple Sclerosis Disability in the Treatment Era
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2016)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
